Bristol-Myers Squibb Co. on Tuesday obtained regulatory approval for its chemotherapy drug Ixempra, also known as ixabepilone, for the treatment of advanced breast cancer. The FDA allowed Bristol-Myers to market Ixempra as a stand-alone treatment for use in women who have failed treatment on three other types of chemotherapy and in combination with Xeloda, a chemotherapy treatment from Roche Holding, to fight breast cancer metastasis.

Related Summaries